Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9,763 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Preclinical and Clinical Pharmacokinetics of JNJ-75220795, an siRNA Therapeutic Targeting PNPLA3, for Metabolic Dysfunction-Associated Steatohepatitis.
Jeon JY, Ayyar VS, Ouchi S, Fabbrini E, Koshkina A, Prusakiewicz JJ, Dallas J, Yang T, Jian W, Kang L, Cofsky K, Rady B, Tamamura R, Saito Y, Yamashita A, Vaughan T, Wendel S, Makimura H, Csonka D, Goyal N. Jeon JY, et al. Among authors: saito y. J Clin Pharmacol. 2024 Dec 9. doi: 10.1002/jcph.6174. Online ahead of print. J Clin Pharmacol. 2024. PMID: 39654352
Phase 1 Trials of PNPLA3 siRNA in I148M Homozygous Patients with MAFLD.
Fabbrini E, Rady B, Koshkina A, Jeon JY, Ayyar VS, Gargano C, DiProspero N, Wendel S, Hegge J, Hamilton H, Ding ZM, Afrazi M, Nicholas A, Pei T, Nakano M, Ouchi S, Saito Y, Yamashita A, Tamamura R, Salazar H, Shapiro C, Yoshihara T, Yonemura T, Inoue S, Matsuoka O, Erion M, Pocai A, Makimura H. Fabbrini E, et al. Among authors: saito y. N Engl J Med. 2024 Aug 1;391(5):475-476. doi: 10.1056/NEJMc2402341. N Engl J Med. 2024. PMID: 39083780 Clinical Trial. No abstract available.
Safety, tolerability and immunogenicity of the ExPEC4V (JNJ-63871860) vaccine for prevention of invasive extraintestinal pathogenic Escherichia coli disease: A phase 1, randomized, double-blind, placebo-controlled study in healthy Japanese participants.
Inoue M, Ogawa T, Tamura H, Hagiwara Y, Saito Y, Abbanat D, van den Dobbelsteen G, Hermans P, Thoelen S, Poolman J, Ibarra de Palacios P. Inoue M, et al. Among authors: saito y. Hum Vaccin Immunother. 2018;14(9):2150-2157. doi: 10.1080/21645515.2018.1474316. Epub 2018 Jun 28. Hum Vaccin Immunother. 2018. PMID: 29771596 Free PMC article. Clinical Trial.
Safety, reactogenicity, and immunogenicity of different doses of 10-valent Extraintestinal Pathogenic Escherichia Coli (ExPEC10V) bioconjugate vaccine (VAC52416) in healthy Japanese adults aged 60-85 years in a randomized, double-blind, phase 1 study.
Haranaka M, Momose A, Nakayama Y, Saito Y, Spiessens B, Davies TA, Dobbelsteen GVD, Poolman J, Sarnecki M. Haranaka M, et al. Among authors: saito y. J Infect Chemother. 2025 Jan;31(1):102514. doi: 10.1016/j.jiac.2024.09.003. Epub 2024 Sep 5. J Infect Chemother. 2025. PMID: 39243886 Free article. Clinical Trial.
A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of osmotic-controlled release oral delivery system methylphenidate HCl in adults with attention-deficit/hyperactivity disorder in Japan.
Takahashi N, Koh T, Tominaga Y, Saito Y, Kashimoto Y, Matsumura T. Takahashi N, et al. Among authors: saito y. World J Biol Psychiatry. 2014 Aug;15(6):488-98. doi: 10.3109/15622975.2013.868925. Epub 2014 Jan 23. World J Biol Psychiatry. 2014. PMID: 24456065 Clinical Trial.
9,763 results